What 	What 	 WP	O
's  	's  	 VBZ	O
new  	new  	 JJ	O
in  	in  	 IN	O
dermato-oncology 	dermato-oncology 	 JJ	B-NP
?  	?  	 .	O
One  	One  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
major  	major  	 JJ	O
advance  	advance  	 NN	O
concerning  	concerning  	 VBG	B-NP
skin  	skin  	 NN	I-NP
carcinoma  	carcinoma  	 NN	I-NP
is  	is  	 VBZ	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
targeted  	targeted  	 JJ	O
therapy 	therapy 	 NN	O
:  	:  	 :	O
anti-patch 	anti-patch 	 FW	B-NP
/ 	/ 	 FW	I-NP
sonic 	sonic 	 FW	I-NP
/ 	/ 	 FW	I-NP
hedgehog  	hedgehog  	 FW	I-NP
for  	for  	 FW	I-NP
basal  	basal  	 FW	I-NP
cell  	cell  	 FW	I-NP
carcinoma  	carcinoma  	 FW	I-NP
( 	( 	 -LRB-	O
BCC 	BCC 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
anti-EGFR  	anti-EGFR  	 JJ	B-NP
for  	for  	 IN	I-NP
squamous  	squamous  	 JJ	I-NP
cell  	cell  	 NN	I-NP
carcinoma  	carcinoma  	 NNS	I-NP
( 	( 	 -LRB-	O
SCC 	SCC 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
These  	These  	 DT	O
therapies  	therapies  	 NNS	O
are  	are  	 VBP	O
indicated  	indicated  	 VBN	O
for  	for  	 IN	O
advanced  	advanced  	 JJ	O
non  	non  	 NNS	B-NP
surgically  	surgically  	 RB	O
removable  	removable  	 JJ	O
tumors 	tumors 	 NNS	O
.  	.  	 .	O
Their  	Their  	 PRP$	O
anti-tumoral  	anti-tumoral  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
shown 	shown 	 VBN	O
,  	,  	 ,	O
their  	their  	 PRP$	O
effect  	effect  	 NN	O
seems  	seems  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
suspensive  	suspensive  	 NNS	B-NP
which  	which  	 WDT	O
raises  	raises  	 VBZ	O
the  	the  	 DT	O
question  	question  	 NN	O
of  	of  	 IN	O
their  	their  	 PRP$	O
tolerability  	tolerability  	 NN	B-NP
for  	for  	 IN	O
long  	long  	 JJ	O
term  	term  	 NN	B-NP
use 	use 	 NN	I-NP
.  	.  	 .	O
Laboratory  	Laboratory  	 NNP	B-NP
work  	work  	 NN	I-NP
have  	have  	 VBP	O
shown  	shown  	 VBN	O
that  	that  	 IN	O
BCC  	BCC  	 NNP	B-NP
and  	and  	 CC	O
SCC  	SCC  	 NNP	B-NP
stem  	stem  	 NN	I-NP
cells  	cells  	 NNS	I-NP
locate  	locate  	 VBP	O
in  	in  	 IN	O
different  	different  	 JJ	O
cell  	cell  	 NN	O
compartments  	compartments  	 NNS	O
and  	and  	 CC	O
follow  	follow  	 VB	O
distinct  	distinct  	 JJ	O
molecular  	molecular  	 JJ	B-NP
events  	events  	 NNS	I-NP
which  	which  	 WDT	O
explains  	explains  	 VBZ	O
their  	their  	 PRP$	O
distinct  	distinct  	 JJ	O
behaviour 	behaviour 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
HPV  	HPV  	 NNP	B-NP
in  	in  	 IN	O
EBDR  	EBDR  	 NNP	B-NP
skin  	skin  	 NN	I-NP
cancers  	cancers  	 NNS	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
ruled  	ruled  	 VBN	O
out 	out 	 RP	O
.  	.  	 .	O
Photodynamic  	Photodynamic  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
induced-immunosuppression  	induced-immunosuppression  	 NN	I-NP
can  	can  	 MD	O
be  	be  	 VB	O
prevented  	prevented  	 VBN	O
by  	by  	 IN	O
lowering  	lowering  	 VBG	O
the  	the  	 DT	O
light  	light  	 JJ	O
fluence 	fluence 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
gene  	gene  	 NN	O
responsible  	responsible  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
Ferguson  	Ferguson  	 NNP	B-NP
Smith  	Smith  	 NNP	I-NP
syndrome  	syndrome  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
identified 	identified 	 VBN	O
:  	:  	 :	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
the  	the  	 DT	O
gene  	gene  	 NN	O
encoding  	encoding  	 VBD	B-NP
TGFBR1 	TGFBR1 	 CD	I-NP
.  	.  	 .	O
Its  	Its  	 PRP$	O
implication  	implication  	 NN	O
in  	in  	 IN	O
SCC  	SCC  	 NNP	B-NP
needs  	needs  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
determined 	determined 	 VBN	O
.  	.  	 .	O
A  	A  	 DT	O
new  	new  	 JJ	O
compound 	compound 	 NN	B-NP
,  	,  	 ,	O
PEP005 	PEP005 	 NNP	B-NP
,  	,  	 ,	O
( 	( 	 -LRB-	O
ingenol  	ingenol  	 FW	B-NP
mebutate 	mebutate 	 FW	I-NP
)  	)  	 -RRB-	O
should  	should  	 MD	O
soon  	soon  	 RB	O
enlarge  	enlarge  	 VB	O
therapeutical  	therapeutical  	 JJ	B-NP
options  	options  	 NNS	I-NP
for  	for  	 IN	I-NP
actinic  	actinic  	 JJ	I-NP
keratosis 	keratosis 	 NN	I-NP
.  	.  	 .	O
Concerning  	Concerning  	 VBG	B-NP
melanoma 	melanoma 	 NN	I-NP
,  	,  	 ,	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
phase  	phase  	 NN	O
III  	III  	 NNP	O
studies  	studies  	 NNS	O
using  	using  	 VBG	O
two  	two  	 CD	O
innovative  	innovative  	 JJ	B-NP
therapies  	therapies  	 NNS	I-NP
( 	( 	 -LRB-	O
anti-Braf  	anti-Braf  	 NNP	B-NP
and  	and  	 CC	O
ipilimumab 	ipilimumab 	 CD	B-NP
)  	)  	 -RRB-	O
have  	have  	 VBP	O
been  	been  	 VBN	O
published 	published 	 VBN	O
.  	.  	 .	O
Comparative  	Comparative  	 JJ	B-NP
study  	study  	 NN	I-NP
between  	between  	 IN	O
anti-Braf  	anti-Braf  	 JJ	B-NP
and  	and  	 CC	O
DTIC  	DTIC  	 NNP	B-NP
has  	has  	 VBZ	O
shown  	shown  	 VBN	O
a  	a  	 DT	O
response  	response  	 NN	B-NP
rate  	rate  	 NN	I-NP
of  	of  	 IN	O
48.4  	48.4  	 CD	O
%  	%  	 NN	O
with  	with  	 IN	O
vemurafenib  	vemurafenib  	 NN	B-NP
and  	and  	 CC	O
5.5  	5.5  	 CD	O
%  	%  	 NN	O
with  	with  	 IN	O
DTIC 	DTIC 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
death  	death  	 NN	O
was  	was  	 VBD	O
diminished  	diminished  	 VBN	O
by  	by  	 IN	O
67  	67  	 CD	O
% 	% 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
results  	results  	 NNS	O
have  	have  	 VBP	O
allowed  	allowed  	 VBN	O
to  	to  	 TO	O
switch  	switch  	 VB	O
to  	to  	 TO	O
vemurafenib  	vemurafenib  	 VB	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
progression  	progression  	 NN	O
under  	under  	 IN	O
DTIC 	DTIC 	 NNP	B-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
initial  	initial  	 JJ	O
response  	response  	 NN	O
is  	is  	 VBZ	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
relapse  	relapse  	 NN	O
in  	in  	 IN	O
a  	a  	 DT	O
majority  	majority  	 NN	O
of  	of  	 IN	O
cases 	cases 	 NNS	O
.  	.  	 .	O
Mechanisms  	Mechanisms  	 NNS	O
of  	of  	 IN	O
this  	this  	 DT	O
resistance  	resistance  	 NN	O
have  	have  	 VBP	O
been  	been  	 VBN	O
studied  	studied  	 VBN	O
and  	and  	 CC	O
the  	the  	 DT	O
inhibition  	inhibition  	 NN	O
of  	of  	 IN	O
several  	several  	 JJ	O
molecules  	molecules  	 NNS	O
involved  	involved  	 VBN	O
in  	in  	 IN	O
different  	different  	 JJ	O
or  	or  	 CC	O
identical  	identical  	 JJ	O
pathway  	pathway  	 NN	O
should  	should  	 MD	O
help  	help  	 VB	O
to  	to  	 TO	O
resolve  	resolve  	 VB	O
that  	that  	 DT	O
problem 	problem 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
combination  	combination  	 NN	B-NP
ipilimumab+  	ipilimumab+  	 NNP	I-NP
DTIC  	DTIC  	 NNP	O
gives  	gives  	 VBZ	O
better  	better  	 JJR	O
results  	results  	 NNS	O
than  	than  	 IN	O
DTIC  	DTIC  	 NNP	B-NP
alone 	alone 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
of  	of  	 IN	O
this  	this  	 DT	O
association  	association  	 NN	O
are  	are  	 VBP	O
slightly  	slightly  	 RB	O
different  	different  	 JJ	O
than  	than  	 IN	O
those  	those  	 DT	O
seen  	seen  	 VBN	O
with  	with  	 IN	O
ipilimumab  	ipilimumab  	 VBG	O
alone 	alone 	 RB	O
.  	.  	 .	O
They  	They  	 PRP	O
must  	must  	 MD	O
be  	be  	 VB	O
known  	known  	 VBN	O
by  	by  	 IN	O
prescribers 	prescribers 	 NN	B-NP
.  	.  	 .	O
Some  	Some  	 DT	O
discussions  	discussions  	 NNS	O
are  	are  	 VBP	O
on  	on  	 IN	O
their  	their  	 PRP$	O
way  	way  	 NN	O
between  	between  	 IN	O
the  	the  	 DT	O
two  	two  	 CD	O
companies  	companies  	 NNS	O
developping  	developping  	 VBP	B-NP
anti-Braf  	anti-Braf  	 JJ	I-NP
and  	and  	 CC	O
ipilimumab  	ipilimumab  	 JJ	O
to  	to  	 TO	O
develop  	develop  	 VB	O
therapeutic  	therapeutic  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
combining  	combining  	 VBG	O
both  	both  	 DT	O
treatments.  	treatments.  	 CD	O
20  	20  	 CD	O
to  	to  	 TO	O
30  	30  	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
taking  	taking  	 VBG	O
anti-Braf  	anti-Braf  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
will  	will  	 MD	O
develop  	develop  	 VB	O
SCC  	SCC  	 NNP	B-NP
( 	( 	 -LRB-	O
due  	due  	 JJ	O
to  	to  	 TO	O
paradoxal  	paradoxal  	 VB	O
activation  	activation  	 VBN	B-NP
of  	of  	 IN	I-NP
MAPK  	MAPK  	 NNP	I-NP
in  	in  	 IN	O
non  	non  	 FW	B-NP
Braf  	Braf  	 FW	I-NP
mutated  	mutated  	 FW	O
cells 	cells 	 FW	O
) 	) 	 -RRB-	O
.  	.  	 .	O
PEG-interferon  	PEG-interferon  	 NNP	B-NP
seems  	seems  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
indicated  	indicated  	 VBN	O
in  	in  	 IN	O
ulcerated  	ulcerated  	 JJ	O
melanoma  	melanoma  	 NN	B-NP
with  	with  	 IN	O
lymph  	lymph  	 JJ	B-NP
node  	node  	 JJ	I-NP
micrometastasis 	micrometastasis 	 NN	I-NP
.  	.  	 .	O
Some  	Some  	 DT	O
other  	other  	 JJ	O
targeted  	targeted  	 JJ	O
molecules  	molecules  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
C-KIT  	C-KIT  	 JJ	B-NP
and  	and  	 CC	O
anti-MEK  	anti-MEK  	 NNS	B-NP
are  	are  	 VBP	O
under  	under  	 IN	O
evaluation 	evaluation 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
effect  	effect  	 NN	O
of  	of  	 IN	O
sunscreens  	sunscreens  	 NN	B-NP
on  	on  	 IN	O
melanoma  	melanoma  	 JJ	B-NP
risk  	risk  	 NN	I-NP
prevention  	prevention  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
reported  	reported  	 VBN	O
in  	in  	 IN	O
an  	an  	 DT	O
Australian  	Australian  	 JJ	O
study 	study 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
low  	low  	 JJ	O
vitamine  	vitamine  	 JJ	O
D  	D  	 NNP	O
status  	status  	 NN	O
is  	is  	 VBZ	O
reported  	reported  	 VBN	O
to  	to  	 TO	O
have  	have  	 VB	O
a  	a  	 DT	O
bad  	bad  	 JJ	O
prognosis  	prognosis  	 NN	O
in  	in  	 IN	O
melanoma  	melanoma  	 NN	B-NP
and  	and  	 CC	O
is  	is  	 VBZ	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
fair  	fair  	 JJ	O
skin  	skin  	 NN	O
patients  	patients  	 NNS	O
at  	at  	 IN	O
risk 	risk 	 NN	O
.  	.  	 .	O
Recommendations  	Recommendations  	 NNS	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
care  	care  	 NN	O
and  	and  	 CC	O
follow  	follow  	 VB	O
up  	up  	 RP	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
Merkel  	Merkel  	 NNP	B-NP
carcinoma  	carcinoma  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
published 	published 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
elevated  	elevated  	 JJ	O
risk  	risk  	 NN	O
of  	of  	 IN	O
positive  	positive  	 JJ	B-NP
sentinel  	sentinel  	 JJ	I-NP
lymph  	lymph  	 JJ	I-NP
nodes  	nodes  	 NN	I-NP
in  	in  	 IN	O
these  	these  	 DT	O
patients  	patients  	 NNS	O
does  	does  	 VBZ	O
not  	not  	 RB	O
allow  	allow  	 VB	O
to  	to  	 TO	O
define  	define  	 VB	O
a  	a  	 DT	O
subgroup  	subgroup  	 NN	B-NP
of  	of  	 IN	O
Merkel  	Merkel  	 NNP	O
patients  	patients  	 NNS	O
that  	that  	 WDT	O
could  	could  	 MD	O
be  	be  	 VB	O
spared  	spared  	 VBN	O
from  	from  	 IN	O
the  	the  	 DT	O
technique 	technique 	 NN	O
.  	.  	 .	O
Sarcoma  	Sarcoma  	 NNP	B-NP
also  	also  	 RB	O
benefit  	benefit  	 VB	O
from  	from  	 IN	O
targeted  	targeted  	 JJ	O
therapy  	therapy  	 NN	O
especially  	especially  	 RB	O
DFSP  	DFSP  	 VBN	O
with  	with  	 IN	O
imatinib 	imatinib 	 NN	B-NP
.  	.  	 .	O
Other  	Other  	 JJ	O
molecules  	molecules  	 NNS	O
among  	among  	 IN	O
which  	which  	 WDT	O
mTOR  	mTOR  	 JJ	B-NP
inhibitors  	inhibitors  	 NNS	I-NP
are  	are  	 VBP	O
being  	being  	 VBG	O
evaluated  	evaluated  	 VBN	O
in  	in  	 IN	O
sarcomas 	sarcomas 	 NN	B-NP
.  	.  	 .	O
A  	A  	 DT	O
collaborative  	collaborative  	 JJ	B-NP
work  	work  	 NN	I-NP
has  	has  	 VBZ	O
allowed  	allowed  	 VBN	O
to  	to  	 TO	O
classify  	classify  	 VB	O
and  	and  	 CC	O
evaluate  	evaluate  	 VB	O
in  	in  	 IN	O
a  	a  	 DT	O
more  	more  	 RBR	O
standardized  	standardized  	 JJ	O
way  	way  	 NN	B-NP
cutaneous  	cutaneous  	 NN	I-NP
T  	T  	 NN	I-NP
lymphomas  	lymphomas  	 NNS	I-NP
and  	and  	 CC	O
should  	should  	 MD	O
help  	help  	 VB	O
future  	future  	 JJ	O
trials 	trials 	 NNS	O
.  	.  	 .	O
Some  	Some  	 DT	O
microRNA  	microRNA  	 NN	B-NP
can  	can  	 MD	O
be  	be  	 VB	O
used  	used  	 VBN	O
as  	as  	 IN	O
diagnostic  	diagnostic  	 JJ	B-NP
tools  	tools  	 NNS	I-NP
or  	or  	 CC	O
therapies  	therapies  	 NNS	O
in  	in  	 IN	O
T  	T  	 NN	B-NP
cell  	cell  	 NN	I-NP
cutaneous  	cutaneous  	 NN	I-NP
lymphomas 	lymphomas 	 NN	I-NP
.  	.  	 .	O
Finally  	Finally  	 RB	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
modern  	modern  	 JJ	O
therapeutical  	therapeutical  	 JJ	B-NP
strategies  	strategies  	 NNS	I-NP
in  	in  	 IN	O
cutaneous  	cutaneous  	 JJ	B-NP
lymphomas  	lymphomas  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
published 	published 	 VBN	O
.  	.  	 .	O
